Kenneth J. Hillan - Net Worth and Insider Trading

Kenneth J. Hillan Net Worth

The estimated net worth of Kenneth J. Hillan is at least $153,263 dollars as of 2024-02-23. Kenneth J. Hillan is the Chief Therapeutics Officer of 23andMe Holding Co and owns about 196,083 shares of 23andMe Holding Co (ME) stock worth over $110,807. Kenneth J. Hillan is the Director of Relypsa Inc and owns about 1,237 shares of Relypsa Inc (RLYP) stock worth over $39,572. Kenneth J. Hillan is also the See Remarks of Achaogen Inc and owns about 115,401 shares of Achaogen Inc (AKAOQ) stock worth over $2,885. Details can be seen in Kenneth J. Hillan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kenneth J. Hillan has not made any transactions after 2022-08-24 and currently still holds the listed stock(s).

Transaction Summary of Kenneth J. Hillan

To

Kenneth J. Hillan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kenneth J. Hillan owns 5 companies in total, including Sangamo Therapeutics Inc () , Zymeworks Inc () , and Achaogen Inc () among others .

Click here to see the complete history of Kenneth J. Hillan’s form 4 insider trades.

Insider Ownership Summary of Kenneth J. Hillan

Ticker Comapny Transaction Date Type of Owner
Sangamo Therapeutics Inc 2020-09-09 director
Zymeworks Inc 2022-12-21 director
Achaogen Inc 2018-06-28 director & See Remarks
Relypsa Inc 2016-09-01 director
23andMe Holding Co 2022-08-24 Head of Therapeutics

Kenneth J. Hillan Latest Holdings Summary

Kenneth J. Hillan currently owns a total of 3 stocks. Among these stocks, Kenneth J. Hillan owns 196,083 shares of 23andMe Holding Co (ME) as of August 24, 2022, with a value of $110,807 and a weighting of 72.3%. Kenneth J. Hillan owns 1,237 shares of Relypsa Inc (RLYP) as of June 7, 2016, with a value of $39,572 and a weighting of 25.82%. Kenneth J. Hillan also owns 115,401 shares of Achaogen Inc (AKAOQ) as of June 26, 2018, with a value of $2,885 and a weighting of 1.88%.

Latest Holdings of Kenneth J. Hillan

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ME 23andMe Holding Co 2022-08-24 196,083 0.57 110,807
RLYP Relypsa Inc 2016-06-07 1,237 31.99 39,572
AKAOQ Achaogen Inc 2018-06-26 115,401 0.03 2,885

Holding Weightings of Kenneth J. Hillan


Kenneth J. Hillan Form 4 Trading Tracker

According to the SEC Form 4 filings, Kenneth J. Hillan has made a total of 1 transactions in 23andMe Holding Co (ME) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in 23andMe Holding Co is the sale of 8,753 shares on August 24, 2022, which brought Kenneth J. Hillan around $31,861.

According to the SEC Form 4 filings, Kenneth J. Hillan has made a total of 0 transactions in Relypsa Inc (RLYP) over the past 5 years. The most-recent trade in Relypsa Inc is the sale of 1,013 shares on June 7, 2016, which brought Kenneth J. Hillan around $19,561.

According to the SEC Form 4 filings, Kenneth J. Hillan has made a total of 0 transactions in Achaogen Inc (AKAOQ) over the past 5 years. The most-recent trade in Achaogen Inc is the sale of 744 shares on June 26, 2018, which brought Kenneth J. Hillan around $7,135.

Insider Trading History of Kenneth J. Hillan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kenneth J. Hillan Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kenneth J. Hillan Ownership Network

Ownership Network List of Kenneth J. Hillan

No Data

Ownership Network Relation of Kenneth J. Hillan


Kenneth J. Hillan Owned Company Details

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Kenneth J. Hillan is the director of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc () Insider Trades Summary

Over the past 18 months, Kenneth J. Hillan made no insider transaction in Sangamo Therapeutics Inc (). Other recent insider transactions involving Sangamo Therapeutics Inc () include a net sale of 6,500,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,500,000 shares of Sangamo Therapeutics Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,500,000 shares.

Sangamo Therapeutics Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Sangamo Therapeutics Inc Insider Transactions

No Available Data

Kenneth J. Hillan Mailing Address

Above is the net worth, insider trading, and ownership report for Kenneth J. Hillan. You might contact Kenneth J. Hillan via mailing address: C/o Achaogen, Inc., 7000 Shoreline Court, Suite 371, South San Francisco Ca 94080.

Discussions on Kenneth J. Hillan

No discussions yet.